IMMUNOVANT, INC. Total Liabilities
IMMUNOVANT, INC. (IMVT) had Total Liabilities of $117.10 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $117.10M.
- 2026-03-31: Liabilities $104.42M.
- 2025-12-31: Liabilities $66.26M.
- 2025-09-30: Liabilities $63.25M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $117.10M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $104.42M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $66.26M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $63.25M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $52.90M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $68.78M 10-K · filed 2026-05-20 |
| 2024-12-31 | $68.31M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $66.65M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $45.02M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $48.61M 10-K · filed 2025-05-29 |
| 2023-12-31 | $32.10M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $40.26M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $51.36M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $43.34M 10-K · filed 2024-05-29 |
| 2022-12-31 | $41.56M 10-Q · filed 2023-02-03 |
| 2022-09-30 | $32.40M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $22.16M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $45.74M 10-K · filed 2023-05-22 |
| 2021-12-31 | $38.03M 10-Q · filed 2022-02-04 |
| 2021-09-30 | $30.34M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $22.50M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $21.01M 10-K · filed 2022-06-08 |
| 2020-12-31 | $18.88M 10-Q · filed 2021-02-16 |
| 2020-09-30 | $15.49M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $22.52M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $15.32M 10-K · filed 2021-06-01 |
| 2019-12-31 | $14.76M 10-Q · filed 2020-02-14 |
| 2019-09-30 | $4.36M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $4.12M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $6.49M 10-K · filed 2020-06-29 |
| 2018-12-31 | $380.45K 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |